OncoMatch/Clinical Trials/NCT06609304
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Is NCT06609304 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Axicabtagene Ciloleucel for lymphoma, b-cell.
Treatment: Axicabtagene Ciloleucel — The goal of this clinical trial is to learn if Axicabtagene Ciloleucel (axi-cel) works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of axi-cel treatment. The main questions it aims to answer are: * Does axi-cel treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment? * What medical problems do participants have when receiving axi-cel treatment? In this investigator-initiated, single-arm clinical trial, participants will: * Receive atezolizumab treatment at 2.0×10\^6 cells/Kg as a one-time therapy. * Visit the clinic as instructed for checkups and tests.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: stem cell transplant
History of stem cell transplantation
Cannot have received: organ transplant
History of organ transplantation
Cannot have received: CAR-T cell therapy
Previous treatment with other modified T-cell therapy
Cannot have received: anti-CD19 therapy
Previous treatment with anti-CD19/CD3 or other anti-CD19 therapies
Cannot have received: immune checkpoint inhibitor
History of any prior systemic immune checkpoint therapy
Cannot have received: cell growth factor or haematopoietic agonist/stimulant
History of short-acting cell growth factors or haematopoietic agonists/stimulants
Lab requirements
Blood counts
adequate bone marrow reserve prior to apheresis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06609304 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages